{"id":74151,"date":"2025-11-06T22:23:11","date_gmt":"2025-11-06T22:23:11","guid":{"rendered":"https:\/\/www.europesays.com\/se\/74151\/"},"modified":"2025-11-06T22:23:11","modified_gmt":"2025-11-06T22:23:11","slug":"klart-usa-sluter-prisavtal-med-novo-nordisk-och-eli-lilly","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/se\/74151\/","title":{"rendered":"Klart: USA sluter prisavtal med Novo Nordisk och Eli Lilly"},"content":{"rendered":"<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Det sade USA:s president, <strong>Donald Trump<\/strong>, i ett uttalande p\u00e5 torsdagen, skriver CNBC.<\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Avtalen inneb\u00e4r att priserna p\u00e5 s\u00e5 kallade GLP-1-l\u00e4kemedel kommer att s\u00e4nkas f\u00f6r Medicare- och Medicaid-f\u00f6rm\u00e5nstagare fr\u00e5n och med 2026. Behandlingarna ska dessutom erbjudas direkt till konsumenter till rabatterade priser via en ny webbplats som Trump-administrationen lanserar i januari, med namnet trumprx.gov.<\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">F\u00f6r f\u00f6rsta g\u00e5ngen kommer Medicare d\u00e4rmed att b\u00f6rja t\u00e4cka fetmal\u00e4kemedel f\u00f6r vissa patienter fr\u00e5n mitten av 2026. Vissa Medicare-patienter kommer att betala en egenavgift p\u00e5 50 dollar per m\u00e5nad f\u00f6r alla godk\u00e4nda anv\u00e4ndningsomr\u00e5den av injicerbara och orala GLP-1-l\u00e4kemedel, inklusive behandling av b\u00e5de diabetes och fetma.<\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Startdosen f\u00f6r kommande fetmal\u00e4kemedel fr\u00e5n<strong> Eli Lilly <\/strong>och <strong>Novo Nordisk<\/strong> kommer att kosta 145 dollar per m\u00e5nad f\u00f6r personer som f\u00e5r l\u00e4kemedlen via Medicare, Medicaid eller Trumprx, enligt en tj\u00e4nsteman inom administrationen.<\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Aff\u00e4rerna beskrivs som n\u00e5gra av de mest politiskt betydelsefulla tillk\u00e4nnagivandena hittills i Trump-administrationens arbete med att tygla de h\u00f6ga amerikanska l\u00e4kemedelskostnaderna genom att knyta dem till de l\u00e4gsta priserna internationellt. <\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Inom ramen f\u00f6r presidentens &#8221;mest gynnade nation&#8221;-politik har han \u00e4ven tillk\u00e4nnagett avtal med Pfizer, AstraZeneca och EMD Serono om att s\u00e4lja vissa l\u00e4kemedel direkt till patienter till rabatterade priser, i utbyte mot undantag fr\u00e5n planerade l\u00e4kemedelstullar.<\/p>\n","protected":false},"excerpt":{"rendered":"Det sade USA:s president, Donald Trump, i ett uttalande p\u00e5 torsdagen, skriver CNBC. Avtalen inneb\u00e4r att priserna p\u00e5&hellip;\n","protected":false},"author":2,"featured_media":15111,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[65],"tags":[72,70,71,6631,1206,369,34,31,33,32,30],"class_list":{"0":"post-74151","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-ekonomi","8":"tag-business","9":"tag-economy","10":"tag-ekonomi","11":"tag-eli-lilly","12":"tag-novo-nordisk","13":"tag-politik","14":"tag-se","15":"tag-svenska","16":"tag-sverige","17":"tag-sweden","18":"tag-swedish"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@se\/115505096512245848","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/74151","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/comments?post=74151"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/74151\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media\/15111"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media?parent=74151"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/categories?post=74151"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/tags?post=74151"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}